OTCM
ODTCD
Market cap54bUSD
, Last price
USD
Name
Odonate Inc
Chart & Performance
Profile
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | |||||||||
Cost of revenue | 21 | 342 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (21) | (342) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 2,119 | (33,302) | |||||||
Tax Rate | |||||||||
NOPAT | (2,140) | 32,960 | |||||||
Net income | 7,325 -82.94% | 42,940 -162.86% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (1,620) | ||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 504 | 469 | |||||||
Long-term debt | 3,590 | 2,299 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 26 | ||||||||
Net debt | (74,383) | (67,022) | |||||||
Cash flow | |||||||||
Cash from operating activities | 8,740 | 1,795 | |||||||
CAPEX | |||||||||
Cash from investing activities | 20,150 | (58,345) | |||||||
Cash from financing activities | (196) | (1,620) | |||||||
FCF | (2,083) | 35,664 | |||||||
Balance | |||||||||
Cash | 57,019 | 48,204 | |||||||
Long term investments | 21,458 | 21,586 | |||||||
Excess cash | 78,477 | 69,790 | |||||||
Stockholders' equity | (384,250) | (391,444) | |||||||
Invested Capital | 494,696 | 495,061 | |||||||
ROIC | 6.64% | ||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 2,870 | ||||||||
Price | 28,000.00 29.63% | ||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT |